Company: VERA
Filing Date: 2025-12-10
Form Type: 424B5
Source: 0001193125-25-314244
Chunk: 12

Company: Vera Therapeutics, Inc.
Filing Date: 2025-12-10
Form: 424B5
Chunk 12
---
 per share after giving effect to this offering                |     |   |      |     |   |  9.19 |
| Dilution in net tangible book value per share to investors purchasing shares in this offering     |     |   |      |     | $ | 33.31 |

If the underwriters exercise in full their option to purchase up to 920,716 additional shares of Class A common stock at the public offering price of $42.50 per share, the as adjusted net tangible book value per share after this offering would be approximately $9.59, representing an increase in net tangible book value of approximately $3.35 per share to our existing stockholders and immediate dilution in net tangible book value of approximately $32.91 per share to new investors purchasing our Class A common stock in this offering at the public offering price. The above table and calculations (other than net tangible book value calculations) are based on 63,894,845 shares of our Class A common stock outstanding as of September 30, 2025, and excludes:

| • |     | 8,408,580 shares of Class A common stock issuable upon the exercise of stock options outstanding under our 2021 Plan,    
 our 2017 Plan or our Inducement Plan at a weighted-average exercise price of $19.10 per share, as of September 30, 2025; |

| • |     | 1,511,420 shares of Class A common stock issuable upon the vesting and settlement of restricted stock units 
 outstanding as of September 30, 2025;                                                                       |

| • |     | 281,150 shares of Class A common stock issuable upon the exercise of stock options outstanding under our 2021                   
 Plan or our Inducement Plan granted subsequent to September 30, 2025, at a weighted-average exercise price of $29.90 per share; |

| • |     | 131,690 shares of Class A common stock issuable upon the vesting and settlement of restricted stock units granted 
 subsequent to September 30, 2025;                                                                                 |

| • |     | 2,406,813 shares of our Class A common stock reserved for future issuance under our 2021 Plan as of September 30, 
 2025;                                                                                                             |

S-10

| • |     | Any future increases in the number of shares of our Class A common stock reserved for issuance under our 2021 Plan; |

| •